Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Belluscura kickstarts review to strengthen capital position

(Sharecast News) - Belluscura's share price plummeted by a quarter on Friday after the medical device group said it was conducting a strategic review to "substantially strengthen its capital position". The company, which develops oxygen enrichment technology spanning broad industries and therapies, said it experienced challenges in late February and March in sourcing product.

Despite a record sales month in April, the main thing holding back the company from turning profitable is access to sufficient working capital to fund bulk orders, which will significantly reduce the unit cost of goods sold.

As a result, Belluscura is now looking at a "range of options", including potential strategic investment, partnerships, alternative funding structures and other corporate initiatives.

The review, which the company stressed does not include a sale, is aimed at "supporting both the company's short-term cash requirements and its longer-term growth and accelerating its path to sustainable profitability".

"For the avoidance of doubt, the strategic review is not for the purposes of soliciting offers for the company pursuant to the City Code on Takeovers and Mergers," it said.

Shares were down 24.6% at 0.51p by 0911 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.